Emergent BioSolutions (EBS) 10-Q 2013 Q3 Quarterly report

Exhibit 10.1

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission.  Double asterisks denote omissions.

SECTION B – SUPPLIES OR SERVICES AND PRICES/COSTS

Option 2  Option for Additional Items Items:

ITEM0003 SUPPLIES/SERVICESBioThrax [**] productBioThrax [**] product[**] upon date of delivery[**] To be delivered in accordance withthe delivery schedule on contractLine(s) Of Accounting:927ZLBG 2642 2013 75-13-09435623RF1101 $[**]927ZLCH 2642 2013 75-13-09435623RF1101 $[**]927ZLCJ 2642 2013 75-13-09435623RF1101 $[**]939ZTGA 2642 2013 75-X-09565664711101 $[**]939ZWUX 2642 2013 75-X-09565664711101 $[**] QTY/UNIT[**]Doses UNIT PRICE$[**] EXTENDED PRICE$[**]

Exercise of Option

1The purpose of this modification is to:

2 Purchase [**] does on CLIN 0003 and provide funding in the amount of $[**]

3 As a result of this modification, total contract value remains the same and total funding is increased by $[**], from $[**] to $[**].

4Add mandatory CDC Local Clause – Needle Exchange, below.

CDC100.0001 Needle Exchange (May 2013)

The Contracting Officer shall insert the following clause in all solicitations and contract including FY13 appropriations.

No funds appropriated in the FY13 Appropriations Act and obligated to this contract may be used to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug.

(End of clause)

TOTAL AMOUNT OBLIGATE ON THIS MODIFICATION: $[**]